Volume 19, Issue 6, Pages (September 2016)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Ulcerative Colitis Treatment Patterns and Cost of Care

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 15, Issue 8, Pages (December 2012)

Volume 18, Issue 5, Pages (July 2015)

Mapping the COPD Assessment Test onto EQ-5D

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 6, Pages (September 2012)

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores

Volume 15, Issue 1, Pages (January 2012)

Volume 17, Issue 2, Pages (March 2014)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia Eva Turk, MA, MBA, Valentina Prevolnik.

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

The Process of Privatization of Health Care Provision in Poland

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Value in Health Regional Issues

Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease Anna Maria Izquierdo-Porrera,

Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,

Value in Health Regional Issues

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

David Rosenthal, MD, Edgar Borrero, MD, Michael D. Clark, MD, Pano A

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Long-Term Survival After Coronary Arterial Grafts in Patients With End-Stage Renal Disease Taro Nakatsu, MD, Nobushige Tamura, MD, PhD, Yutaka Sakakibara,

Mohammed Al-Omran, MD, MSc, Muhammad M

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Value in Health Regional Issues

Statin use and clinical outcomes among pneumonia patients

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Todd R. Vogel, MD, MPH, Robin L. Kruse, PhD

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.

Victoria I. Ignatyeva, MPH, Johan L

Limitations of Hospital Volume as a Measure of Quality of Care for Coronary Artery Bypass Graft Surgery Karl F. Welke, MD, Mitchell J. Barnett, PharmD,

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 19, Issue 6, Pages 852-860 (September 2016) Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database Kathy L. Schulman, MA, Lois E. Lamerato, PhD, Mehul R. Dalal, PhD, Jennifer Sung, PharmD, MS, Mehul Jhaveri, PharmD, Andrew Koren, MD, Usha G. Mallya, PhD, JoAnne M. Foody, MD Value in Health Volume 19, Issue 6, Pages 852-860 (September 2016) DOI: 10.1016/j.jval.2016.03.1858 Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Patient disposition. CV, cardiovascular risk; HAP, Health Alliance Plan. *High-intensity statin: atorvastatin 40 or 80 mg; rosuvastatin 10, 20, or 40 mg; and simvastatin 80 mg. †Patients were selected randomly to preserve the 80/20 split between moderate- to low-intensity and high-intensity statin patients observed in the administrative database, with 40% on simvastatin, 40% on atorvastatin, and 20% on other statins. ‡Ten patients were excluded because of data quality issues. §Patients with a diagnosis of diabetes, coronary heart disease, or peripheral artery disease in the 12 mo before the qualifying event. Value in Health 2016 19, 852-860DOI: (10.1016/j.jval.2016.03.1858) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions